pLPCX

Retroviral vector for transient or stable constitutive expression of a gene.

Sequence Author: Clontech (TaKaRa)

|Download SnapGene Viewer
No matches
SspI (5902) XmnI (5697) PvuI (5468) FspI (5320) AseI (5270) PspFI (4513) BseYI (4509) AflIII - PciI (4205) BspQI - SapI (4089) BspEI * (3927) XbaI (3300) AscI (443) PshAI (577) SpeI (726) BsrGI (1348) BfuAI - BspMI (1478) AgeI (1504) BsiWI (1621) RsrII (1681) DraIII (2136) CMV enhancer BtgZI (2612) SnaBI (2618) BglII (2887) PaeR7I - XhoI (2891) HindIII (2900) BstBI (2905) EcoRI (2907) NotI (2940) BspDI - ClaI (2959) pLPCX 6264 bp
SspI  (5902)
1 site
A A T A T T T T A T A A
XmnI  (5697)
1 site
G A A N N N N T T C C T T N N N N A A G
PvuI  (5468)
1 site
C G A T C G G C T A G C
FspI  (5320)
1 site
T G C G C A A C G C G T
AseI  (5270)
1 site
A T T A A T T A A T T A
PspFI  (4513)
1 site
C C C A G C G G G T C G
BseYI  (4509)
1 site
C C C A G C G G G T C G

After cleavage, BseYI can remain bound to DNA and alter its electrophoretic mobility.
AflIII  (4205)
1 site
A C R Y G T T G Y R C A

Sticky ends from different AflIII sites may not be compatible.
PciI  (4205)
1 site
A C A T G T T G T A C A

PciI is inhibited by nonionic detergents.
BspQI  (4089)
1 site
G C T C T T C N C G A G A A G N N N N

Sticky ends from different BspQI sites may not be compatible.
SapI  (4089)
1 site
G C T C T T C N C G A G A A G N N N N

Sticky ends from different SapI sites may not be compatible.
SapI gradually settles in solution, so a tube of SapI should be mixed before removing an aliquot.
BspEI  (3927)
1 site
T C C G G A A G G C C T
* Blocked by Dam methylation.
XbaI  (3300)
1 site
T C T A G A A G A T C T
AscI  (443)
1 site
G G C G C G C C C C G C G C G G
PshAI  (577)
1 site
G A C N N N N G T C C T G N N N N C A G

PshAI quickly loses activity at 37°C, but can be used at 25°C for long incubations.
SpeI  (726)
1 site
A C T A G T T G A T C A
BsrGI  (1348)
1 site
T G T A C A A C A T G T

BsrGI is typically used at 37°C, but is even more active at 60°C.
BfuAI  (1478)
1 site
A C C T G C ( N ) 4 T G G A C G ( N ) 4 ( N ) 4

Efficient cleavage requires at least two copies of the BfuAI recognition sequence.
Sticky ends from different BfuAI sites may not be compatible.
BfuAI is typically used at 50°C, but is 50% active at 37°C.
BspMI  (1478)
1 site
A C C T G C ( N ) 4 T G G A C G ( N ) 4 ( N ) 4

Efficient cleavage requires at least two copies of the BspMI recognition sequence.
Sticky ends from different BspMI sites may not be compatible.
AgeI  (1504)
1 site
A C C G G T T G G C C A
BsiWI  (1621)
1 site
C G T A C G G C A T G C

BsiWI is typically used at 55°C, but is 50% active at 37°C.
RsrII  (1681)
1 site
C G G W C C G G C C W G G C

Efficient cleavage requires at least two copies of the RsrII recognition sequence.
Sticky ends from different RsrII sites may not be compatible.
For full activity, add fresh DTT.
DraIII  (2136)
1 site
C A C N N N G T G G T G N N N C A C

Sticky ends from different DraIII sites may not be compatible.
BtgZI  (2612)
1 site
G C G A T G ( N ) 10 C G C T A C ( N ) 10 ( N ) 4

Sticky ends from different BtgZI sites may not be compatible.
After cleavage, BtgZI can remain bound to DNA and alter its electrophoretic mobility.
BtgZI is typically used at 60°C, but is 75% active at 37°C.
SnaBI  (2618)
1 site
T A C G T A A T G C A T
BglII  (2887)
1 site
A G A T C T T C T A G A
PaeR7I  (2891)
1 site
C T C G A G G A G C T C

PaeR7I does not recognize the sequence CTCTCGAG.
XhoI  (2891)
1 site
C T C G A G G A G C T C
HindIII  (2900)
1 site
A A G C T T T T C G A A
BstBI  (2905)
1 site
T T C G A A A A G C T T
EcoRI  (2907)
1 site
G A A T T C C T T A A G
NotI  (2940)
1 site
G C G G C C G C C G C C G G C G
BspDI  (2959)
1 site
A T C G A T T A G C T A
ClaI  (2959)
1 site
A T C G A T T A G C T A
AmpR
5025 .. 5885  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
   Segment 2:  
   5025 .. 5816  =  792 bp
   263 amino acids  =  28.9 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
AmpR
5025 .. 5885  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
   Segment 1:  signal sequence  
   5817 .. 5885  =  69 bp
   23 amino acids  =  2.6 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
AmpR
5025 .. 5885  =  861 bp
286 amino acids  =  31.5 kDa
2 segments
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and related antibiotics
PuroR
1565 .. 2164  =  600 bp
199 amino acids  =  21.5 kDa
Product: puromycin N-acetyltransferase
confers resistance to puromycin
PuroR
1565 .. 2164  =  600 bp
199 amino acids  =  21.5 kDa
Product: puromycin N-acetyltransferase
confers resistance to puromycin
3' LTR
3003 .. 3596  =  594 bp
long terminal repeat from Moloney murine leukemia virus
3' LTR
3003 .. 3596  =  594 bp
long terminal repeat from Moloney murine leukemia virus
5' LTR
1 .. 589  =  589 bp
long terminal repeat from Moloney murine sarcoma virus
5' LTR
1 .. 589  =  589 bp
long terminal repeat from Moloney murine sarcoma virus
ori
4266 .. 4854  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin of replication
ori
4266 .. 4854  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin of replication
gag (truncated)
1052 .. 1468  =  417 bp
truncated MMLV gag gene lacking the start codon
gag (truncated)
1052 .. 1468  =  417 bp
truncated MMLV gag gene lacking the start codon
CMV enhancer
2339 .. 2642  =  304 bp
human cytomegalovirus immediate early enhancer
CMV enhancer
2339 .. 2642  =  304 bp
human cytomegalovirus immediate early enhancer
CMV promoter
2643 .. 2846  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
CMV promoter
2643 .. 2846  =  204 bp
human cytomegalovirus (CMV) immediate early promoter
MMLV Ψ
652 .. 851  =  200 bp
packaging signal of Moloney murine leukemia virus (MMLV)
MMLV Ψ
652 .. 851  =  200 bp
packaging signal of Moloney murine leukemia virus (MMLV)
AmpR promoter
5886 .. 5990  =  105 bp
AmpR promoter
5886 .. 5990  =  105 bp
MCS
2887 .. 2963  =  77 bp
multiple cloning site
MCS
2887 .. 2963  =  77 bp
multiple cloning site
loxP
3849 .. 3882  =  34 bp
Cre-mediated recombination occurs in the 8-bp core sequence (GCATACAT).
loxP
3849 .. 3882  =  34 bp
Cre-mediated recombination occurs in the 8-bp core sequence (GCATACAT).
loxP
3942 .. 3975  =  34 bp
Cre-mediated recombination occurs in the 8-bp core sequence (GCATACAT).
loxP
3942 .. 3975  =  34 bp
Cre-mediated recombination occurs in the 8-bp core sequence (GCATACAT).
ORF:  3955 .. 4212  =  258 bp
ORF:  85 amino acids  =  9.9 kDa
ORF:  5155 .. 5421  =  267 bp
ORF:  88 amino acids  =  9.2 kDa
ORF:  1565 .. 2164  =  600 bp
ORF:  199 amino acids  =  21.5 kDa
ORF:  739 .. 999  =  261 bp
ORF:  86 amino acids  =  9.5 kDa
ORF:  3420 .. 3710  =  291 bp
ORF:  96 amino acids  =  10.5 kDa
ORF:  5025 .. 5885  =  861 bp
ORF:  286 amino acids  =  31.5 kDa
ORF:  1460 .. 2215  =  756 bp
ORF:  251 amino acids  =  26.0 kDa
Click here to try SnapGene

Download pLPCX.dna file

SnapGene

SnapGene is the easiest way to plan, visualize and document your everyday molecular biology procedures

  • Fast accurate construct design for all major molecular cloning techniques
  • Validate sequenced constructs using powerful alignment tools
  • Customize plasmid maps with flexible annotation and visualization controls
  • Automatically generate a rich graphical history of every edit and procedure

SnapGene Viewer

SnapGene Viewer is free software that allows molecular biologists to create, browse, and share richly annotated sequence files.

  • Gain unparalleled visibility of your plasmids, DNA and protein sequences
  • Annotate features on your plasmids using the curated feature database
  • Store, search, and share your sequences, files and maps

Individual Sequences & Maps

The maps, notes, and annotations in the zip file on this page are copyrighted material. This material may be used without restriction by academic, nonprofit, and governmental entities, except that the source must be cited as ’’www.snapgene.com/resources’’. Commercial entities must contact GSL Biotech LLC for permission and terms of use.

Discover the most user-friendly molecular biology experience.